Skip to content
Trial Eligibility
Menu

GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study

NCT07588984

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement. FLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Obesity & Overweight
  • Weight Loss
  • Preventative Health
  • Body Weight
  • Cardiovascular Disease Risk Factor

Eligibility basics and study details

Study type
Observational
Phase
Not applicable
Ages
18 to 64 years
Sex
All
Healthy volunteers
Not accepted
Sponsor
Noom Inc.
Last updated on ClinicalTrials.gov
November 16, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

New Jersey · 1

  • Noom, Inc. · Princeton, NJ

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.